Targets for Ibrutinib Beyond B Cell Malignancies-Reference-Cited by-同舟云学术

Targets for Ibrutinib Beyond B Cell Malignancies

Published:2015-08-18 Issue:3 Volume:82 Page:208-217
ISSN:0300-9475
Container-title:Scandinavian Journal of Immunology
language:en
Short-container-title:Scand J Immunol

Author:

Berglöf A.¹,Hamasy A.¹,Meinke S.²,Palma M.³⁴,Krstic A.⁵,Månsson R.⁵,Kimby E.⁶,Österborg A.³,Smith C. I. E.¹

Affiliation:

1. Department of Laboratory Medicine Karolinska Institutet Stockholm Sweden

2. Center for Hematology and Regenerative Medicine Karolinska Institutet and Department of Clinical Immunology and Transfusion Medicine Karolinska University Hospital Huddinge Stockholm Sweden

3. Department of Hematology Karolinska University Hospital Solna Stockholm Sweden

4. Department of Oncology and Pathology Karolinska Institutet Stockholm Sweden

5. Center for Hematology and Regenerative Medicine Karolinska Institutet Stockholm Sweden

6. Department of Medicine Karolinska Institutet Stockholm Sweden

Funder

Swedish Cancer Society

Publisher

Wiley

Subject

Immunology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12333

Reference103 articles.

1. Ibrutinib: First Global Approval

2. Targeted covalent drugs of the kinase family

3. Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase

4. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling

5. Agammaglobulinemia: causative mutations and their implications for novel therapies

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10

2. Characterization of ibrutinib's effects on the morphology, proliferation, phenotype, viability, and anti-inflammatory potential of adipose-derived mesenchymal stromal cells;Scientific Reports;2024-08-28

3. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

4. The Evolving Role of Bruton’s Tyrosine Kinase Inhibitors in B Cell Lymphomas;International Journal of Molecular Sciences;2024-07-09

5. A New Scoring System for the Evaluation of Ibrutinib-Associated Arrhythmias in Chronic Lymphocytic Leukemia: The ACEF Score;Turkish Journal of Hematology;2024-05-30